GlassScriptPhysician profile
Kevin N Sheppard
NPI 1538219530
$20,312.90
in general payments reported to CMS, 2019-2025
56 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,849 · 2020: $1,950 · 2021: $3,577 · 2022: $6,594 · 2023: $3,331 · 2024: $13.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,430.04 | 2019-2023 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $2,101.17 | 2019-2023 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $1,216.17 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,212.29 | 2019-2023 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $1,103.61 | 2019-2023 | |
| Glaxosmithkline, LLC. | $819.61 | 2021-2023 | Arexvy, Trelegy Ellipta, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $713.47 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $699.17 | 2019-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $685.33 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $650.58 | 2019-2020 | |
| Gilead Sciences, INC. | $614.35 | 2019-2023 | Epclusa |
| Lilly USA, LLC | $531.93 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Esperion Therapeutics, INC. | $509.66 | 2020-2022 | |
| Medtronic, INC. | $478.26 | 2021-2022 | |
| Pfizer INC. | $400.38 | 2019-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.